Log in

NASDAQ:KTOVKITOV PHARMA LT/S Stock Price, Forecast & News

-0.03 (-3.09 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $0.87
50-Day Range
MA: $0.84
52-Week Range
Now: $0.87
Volume9.55 million shs
Average Volume13.58 million shs
Market Capitalization$136.81 million
P/E RatioN/A
Dividend YieldN/A
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study. It is also developing NT219, a small molecule that targets two pathways involved in cancer drug resistance. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd was founded in 2010 and is headquartered in Tel Aviv, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KTOV



Sales & Book Value

Annual Sales$1 million
Book Value$0.56 per share



Market Cap$136.81 million
Next Earnings DateN/A
OptionableNot Optionable
-0.03 (-3.09 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KTOV News and Ratings via Email

Sign-up to receive the latest news and ratings for KTOV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

KITOV PHARMA LT/S (NASDAQ:KTOV) Frequently Asked Questions

How has KITOV PHARMA LT/S's stock been impacted by COVID-19 (Coronavirus)?

KITOV PHARMA LT/S's stock was trading at $0.3551 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KTOV shares have increased by 145.0% and is now trading at $0.87.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of KITOV PHARMA LT/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KITOV PHARMA LT/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for KITOV PHARMA LT/S

What price target have analysts set for KTOV?

1 brokerages have issued 12 month price objectives for KITOV PHARMA LT/S's shares. Their forecasts range from $3.00 to $3.00. On average, they anticipate KITOV PHARMA LT/S's share price to reach $3.00 in the next year. This suggests a possible upside of 244.8% from the stock's current price.
View analysts' price targets for KITOV PHARMA LT/S

Has KITOV PHARMA LT/S been receiving favorable news coverage?

Media stories about KTOV stock have trended very negative on Sunday, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. KITOV PHARMA LT/S earned a news impact score of -3.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about KITOV PHARMA LT/S

Who are some of KITOV PHARMA LT/S's key competitors?

What other stocks do shareholders of KITOV PHARMA LT/S own?

Who are KITOV PHARMA LT/S's key executives?

KITOV PHARMA LT/S's management team includes the following people:
  • Dr. John Paul Waymack, Founder, Chairman & Chief Medical Officer (Age 67)
  • Mr. Isaac Israel, CEO & Director (Age 41)
  • Dr. Hadas Reuveni, Founder & CTO of TyrNovo (Age 52)
  • Mr. Simcha Rock CPA, M.B.A., CPA, MBA, Strategic Advisor & Director (Age 69)
  • Dr. Gil Ben-Menachem M.B.A., MSc, MBA, Ph.D., VP of Bus. Devel. & Director (Age 52)


(KTOV) raised $13 million in an initial public offering on Friday, November 20th 2015. The company issued 3,200,000 shares at a price of $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar acted as the underwriters for the IPO.

What is KITOV PHARMA LT/S's stock symbol?

KITOV PHARMA LT/S trades on the NASDAQ under the ticker symbol "KTOV."

Who are KITOV PHARMA LT/S's major shareholders?

KITOV PHARMA LT/S's stock is owned by a number of institutional and retail investors. Top institutional shareholders include UBS Group AG (0.18%), Virtu Financial LLC (0.07%), Bedel Financial Consulting Inc. (0.02%), Raymond James Financial Services Advisors Inc. (0.02%) and TRUE Private Wealth Advisors (0.02%).

Which institutional investors are buying KITOV PHARMA LT/S stock?

KTOV stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Virtu Financial LLC, Bedel Financial Consulting Inc., Raymond James Financial Services Advisors Inc., and TRUE Private Wealth Advisors.

How do I buy shares of KITOV PHARMA LT/S?

Shares of KTOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is KITOV PHARMA LT/S's stock price today?

One share of KTOV stock can currently be purchased for approximately $0.87.

How big of a company is KITOV PHARMA LT/S?

KITOV PHARMA LT/S has a market capitalization of $136.81 million and generates $1 million in revenue each year. The company earns $-5,850,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. KITOV PHARMA LT/S employs 10 workers across the globe.

What is KITOV PHARMA LT/S's official website?

The official website for KITOV PHARMA LT/S is www.kitovpharma.com.

How can I contact KITOV PHARMA LT/S?

KITOV PHARMA LT/S's mailing address is ONE AZRIELI CENTER ROUND TOWER 132 MENACHEM BEGIN ROAD, TEL AVIV L3, 6701101. The company can be reached via phone at 972-3933-3121 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.